Cyclacel Pharmaceuticals Total Debt vs. Return On Equity

CYCCP Preferred Stock  USD 6.75  0.19  2.74%   
Based on Cyclacel Pharmaceuticals' profitability indicators, Cyclacel Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Cyclacel Pharmaceuticals' ability to earn profits and add value for shareholders.
For Cyclacel Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cyclacel Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cyclacel Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cyclacel Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cyclacel Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
To learn how to invest in Cyclacel Preferred Stock, please use our How to Invest in Cyclacel Pharmaceuticals guide.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclacel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Cyclacel Pharmaceuticals Return On Equity vs. Total Debt Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Cyclacel Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Cyclacel Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Cyclacel Pharmaceuticals is rated below average in total debt category among its peers. It is rated third in return on equity category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cyclacel Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Cyclacel Total Debt vs. Competition

Cyclacel Pharmaceuticals is rated below average in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 237.94 Million. Cyclacel Pharmaceuticals adds roughly 113,000 in total debt claiming only tiny portion of equities under Health Care industry.
Total debt  Workforce  Capitalization  Revenue  Valuation

Cyclacel Return On Equity vs. Total Debt

Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Cyclacel Pharmaceuticals

Total Debt

 = 

Bonds

+

Notes

 = 
113 K
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Cyclacel Pharmaceuticals

Return On Equity

 = 

Net Income

Total Equity

 = 
-0.6
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.

Cyclacel Return On Equity Comparison

Cyclacel Pharmaceuticals is currently under evaluation in return on equity category among its peers.

Cyclacel Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Cyclacel Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cyclacel Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Cyclacel Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Cyclacel Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuti operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.

Cyclacel Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Cyclacel Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cyclacel Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cyclacel Pharmaceuticals' important profitability drivers and their relationship over time.

Use Cyclacel Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclacel Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclacel Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Cyclacel Pharmaceuticals Pair Trading

Cyclacel Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Cyclacel Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclacel Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclacel Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclacel Pharmaceuticals to buy it.
The correlation of Cyclacel Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclacel Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclacel Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclacel Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Cyclacel Pharmaceuticals position

In addition to having Cyclacel Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Casinos Thematic Idea Now

Casinos
Casinos Theme
Companies that are related to providing casino-type services across multiple geographical areas. The Casinos theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Casinos Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Cyclacel Preferred Stock Analysis

When running Cyclacel Pharmaceuticals' price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.